Every Form 4 that SpyGlass Pharma, Inc. (SGP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SGP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGP filings page.
Investment funds managed by RA Capital Management reported several insider transactions in SpyGlass Pharma, Inc. common stock surrounding the company’s initial public offering. RA Capital Healthcare Fund and RA Capital Nexus Fund III converted multiple series of preferred stock into common stock on a one-for-one basis immediately before the IPO.
The funds then indirectly bought additional SpyGlass common shares in open-market or private transactions on February 9, 2026, purchasing 3,441,966 shares at $16 per share through the Fund and 248,034 shares at $16 per share through Nexus Fund III. The reporting persons, including RA Capital entities and principals Peter Kolchinsky and Rajeev Shah, are listed as directors and, in most cases, 10% owners and disclaim beneficial ownership beyond their pecuniary interests.
A director of SpyGlass Pharma, Inc. filed an amended insider trading report updating how many shares are indirectly owned following the company’s initial public offering. The filing shows indirect beneficial ownership of 3,310,619 shares of common stock held through Vensana Capital I, L.P.
The amendment restates derivative holdings to reflect that shares of Series B, Series C-1, Series C-2 and Series D preferred stock, totaling 1,690,230, 548,067, 548,067 and 359,255 shares respectively, automatically converted on a one-for-one basis into common stock before the IPO closing.
SpyGlass Pharma, Inc. reported insider transactions involving entities associated with director and 10% owner Ali Behbahani on February 9, 2026. Several series of preferred stock automatically converted on a one-for-one basis into common stock immediately before the closing of the company’s initial public offering on that date.
The converted shares were held by New Enterprise Associates funds NEA 17 and NEA 16, for which Behbahani is a manager of the respective general partners. He disclaims beneficial ownership of portions in which he has no pecuniary interest. In addition, an NEA 17-related entity acquired 937,500 shares of common stock in an open‑market or private purchase at $16 per share, reported as indirect ownership.
SpyGlass Pharma, Inc. reported insider-related equity changes involving a 10% owner on February 9, 2026. Investment entities NEA 17 and NEA 16, which are the direct beneficial owners of the securities, had multiple series of preferred stock automatically convert on a one-for-one basis into common stock before the closing of SpyGlass Pharma’s initial public offering on February 9, 2026.
On the same date, an entity associated with NEA 17 indirectly purchased 937,500 shares of common stock at $16 per share. After these transactions, 6,035,038 shares of common stock were indirectly beneficially owned through NEA 17 and 1,357,263 shares through NEA 16, while the reporting person disclaims beneficial ownership of portions in which he has no pecuniary interest.
SpyGlass Pharma’s 10% holder Baskett Forest, through investment funds NEA 17 and NEA 16, reported multiple indirect acquisitions of common stock on February 9, 2026. Several series of preferred stock automatically converted into common stock on a one-for-one basis in connection with the company’s initial public offering.
In addition, an affiliated fund indirectly bought 937,500 shares of common stock at $16 per share, bringing its indirect common stock holdings reported in this filing to 6,035,038 shares, while another affiliated fund reported 1,357,263 indirectly held shares. Baskett Forest disclaims beneficial ownership of portions of these positions where there is no pecuniary interest.
New Enterprise Associates 17, L.P., a 10% owner of SpyGlass Pharma, Inc., reported several equity changes tied to the company’s initial public offering. On February 9, 2026, multiple series of preferred stock automatically converted on a one-for-one basis into common stock before the IPO closed.
These conversions increased NEA 17’s direct holdings to 5,097,538 shares of common stock. On the same date, NEA 17 also purchased 937,500 shares of common stock at $16 per share, bringing its directly held position to 6,035,038 common shares.
The securities are directly held by NEA 17 and indirectly by NEA Partners 17, L.P., NEA 17 GP, LLC, and specified individual managers, who disclaim beneficial ownership of portions in which they have no pecuniary interest.
SpyGlass Pharma, Inc. reported insider activity linked to investment fund New Enterprise Associates 17, L.P. (NEA 17), with Rick Yang as the Section 16 reporting person. On February 9, 2026, all Series B, Series C-1, Series C-2 and Series D preferred stock automatically converted on a one-for-one basis into the same number of common shares in connection with the company’s initial public offering.
On the same date, NEA 17 also reported an indirect open‑market or private purchase of 937,500 shares of common stock at $16 per share, bringing its indirectly held common stock position to 6,035,038 shares. The filing explains that NEA 17 is the direct beneficial owner and that Rick Yang disclaims beneficial ownership of any portion in which he has no pecuniary interest.
SpyGlass Pharma’s 10% owner Mohamad Makhzoumi reported IPO-related share activity on February 9, 2026. Investment entities associated with him converted multiple series of preferred stock into common stock on a one-for-one basis immediately before the company’s initial public offering.
The filing also shows an indirect open-market or private purchase of 937,500 shares of common stock at $16 per share, bringing related indirect holdings to 6,035,038 common shares under the NEA 17 structure. Additional indirect common shares are held through NEA 16 entities. Makhzoumi disclaims beneficial ownership of portions of these fund-held securities where he has no pecuniary interest.
SpyGlass Pharma’s Form 4 shows venture funds affiliated with Scott D. Sandell increasing their indirect common stock holdings around the company’s initial public offering. On February 9, 2026, multiple series of preferred stock automatically converted one-for-one into common shares before the IPO closing.
NEA 17-related entities ended with 6,035,038 shares of common stock held indirectly, including an open-market or private purchase of 937,500 shares at $16 per share. NEA 16-related entities held 1,357,263 common shares indirectly. The footnotes state Sandell disclaims beneficial ownership of portions of these fund-held securities in which he has no pecuniary interest.
SpyGlass Pharma 10% owner Chang Carmen, through New Enterprise Associates funds, reported multiple indirect transactions on February 9, 2026. All Series A, B, C-1, C-2 and D preferred stock automatically converted on a one-for-one basis into common stock in connection with SpyGlass Pharma’s initial public offering. In addition, an affiliated fund indirectly purchased 937,500 shares of common stock at $16 per share. The filing notes that Carmen disclaims beneficial ownership of portions of NEA 16 and NEA 17 holdings in which there is no pecuniary interest.
SpyGlass Pharma’s major shareholder entity reported IPO-related conversions and a large share purchase. An entity associated with Edward T. Mathers, New Enterprise Associates 17, L.P. (NEA 17), a 10% owner, converted Series B, C-1, C-2 and D preferred stock into 1,619,240, 1,370,168, 1,370,168 and 737,962 shares of common stock, respectively, on February 9, 2026, immediately before the closing of the company’s initial public offering. NEA 17 also indirectly bought 937,500 additional common shares at $16 per share, bringing its indirectly held common stock position reported here to 6,035,038 shares. Mathers is a manager of NEA 17’s general partner and disclaims beneficial ownership of portions of NEA 17’s holdings in which he has no pecuniary interest.
SpyGlass Pharma, Inc. reported that investment entities associated with 10% owner Paul Edward Walker indirectly acquired common stock around the company’s initial public offering. On February 9, 2026, all outstanding preferred stock series automatically converted into common stock on a one-for-one basis before the IPO closing, creating large indirect common holdings for New Enterprise Associates funds.
On the same date, an entity linked to Walker also indirectly purchased 937,500 shares of common stock at $16 per share, bringing that entity’s indirect common holdings to 6,035,038 shares, as referenced in Note 2. Separate entities referenced in Note 3 indirectly held 1,357,263 shares of common stock after related conversions.
SpyGlass Pharma director-affiliated entity increased its indirect stake through a conversion and open-market purchase. On 02/09/2026, 1,875,013 shares of Series D preferred stock automatically converted on a one-for-one basis into 1,875,013 shares of common stock immediately before SpyGlass Pharma’s initial public offering. On the same date, an affiliated entity purchased 312,500 additional common shares at $16 per share. Following these transactions, 2,187,513 common shares were reported as indirectly owned through Coöperatieve Gilde Healthcare VG VI U.A. and related Gilde Healthcare entities, with voting and dispositive power primarily held by Gilde Healthcare VG VI Management B.V. and certain individuals, who, along with the reporting person, disclaim beneficial ownership except for their pecuniary interests.
Khan Bilal Arshad, a director of SpyGlass Pharma, Inc., reported buying common stock in two open-market transactions on February 9, 2026 at $16 per share. He purchased 20,000 shares directly, bringing his direct holdings to 25,450 shares.
An affiliated entity, New World Medical, Inc., bought an additional 115,000 shares, increasing its indirect holdings reported for him to 251,427 shares. He is New World Medical’s Chief Executive Officer with voting and investment control but disclaims beneficial ownership of those shares except for his pecuniary interest.
SpyGlass Pharma director-affiliated entity reports IPO-related conversions and share purchase. Investment vehicle Vensana Capital I, L.P., associated with director Kirk G. Nielsen, converted multiple series of preferred stock into Common Stock on 02/09/2026 immediately before SpyGlass Pharma’s initial public offering.
The preferred shares converted to Common Stock at a one-for-5.7329 ratio without additional payment. Following these derivative conversions, Vensana Capital I, L.P. indirectly held 3,145,619 Common shares, then acquired an additional 165,000 Common shares in an open‑market purchase at $16 per share, bringing its indirect holdings to 3,310,619 Common shares.
SpyGlass Pharma insider entity Vensana Capital I, L.P., through its affiliated general partner, reported multiple transactions in connection with the company’s initial public offering. On February 9, 2026, its holdings of Series B, Series C‑1, Series C‑2 and Series D preferred stock automatically converted into common stock on a one‑for‑5.7329 basis immediately before the IPO, resulting in indirect ownership of 3,145,619 common shares. On the same date, the entity also purchased 165,000 common shares at $16 per share, bringing its total indirect common stock position to 3,310,619 shares, which are held by Vensana Capital I, L.P. The filing notes that Vensana Capital I GP, LLC and its managing directors, including board member Kirk Nielsen and Peter Justin Klein, may be deemed to share voting and investment power, but they disclaim beneficial ownership except to the extent of their pecuniary interests.
RA CAPITAL MANAGEMENT, L.P. reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
Behbahani Ali reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
Nielsen Kirk G. reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
SpyGlass Pharma, Inc. director Zachary Scheiner was granted a stock option covering 27,400 shares of common stock at an exercise price of $16 per share on February 5, 2026. The option vests in equal monthly installments over 36 months, conditioned on his continuing service as an Outside Director.
According to the filing, Scheiner holds this option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P. Any net cash or stock received upon exercise must be turned over to RA Capital Management, L.P. to offset advisory fees, and Scheiner disclaims beneficial ownership of the option and underlying shares.
Khan Bilal Arshad reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 13,700 shares. Following the reported transactions, holdings were 13,700 shares.
SpyGlass Pharma director Habib J. Dable was granted stock options to acquire 27,400 shares of common stock on February 5, 2026. The options have an exercise price of $16 per share and were awarded as a derivative security grant.
According to the award terms, the options vest over three years, with one thirty-sixth of the shares vesting each month after the grant date, so long as Dable continues to serve as an Outside Director under the company’s 2026 Equity Incentive Plan.
Pardo Geoffrey B reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
Dybbs Michael reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
SpyGlass Pharma director Elizabeth G. O'Farrell received a stock option grant covering 13,700 shares of common stock on February 5, 2026. The option has an exercise price of $16 per share, expires on February 5, 2036, and was awarded at no cost to her.
The option will vest 100% on the earlier of one year after the grant date or immediately before the next annual meeting of stockholders, provided she continues as an Outside Director. Following this grant, she beneficially owns options for 13,700 shares directly.
Dennewill James Robert Jr. reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 105,000 shares. Following the reported transactions, holdings were 105,000 shares.
Pujara Chetan Pratap reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 105,000 shares. Following the reported transactions, holdings were 105,000 shares.
SpyGlass Pharma, Inc. director and officer Malik Y. Kahook received a grant of stock options covering 105,000 shares of common stock on February 5, 2026 at an exercise price of $16 per share. These options are held as direct beneficial ownership.
The options vest over time: 25% of the shares vest on the one-year anniversary of the February 5, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following three years. The options expire on February 5, 2036, and this grant brings his total derivative holdings from this award to 105,000 options.
SpyGlass Pharma, Inc. granted its Chief Financial Officer, Jean-Frederic Viret, a stock option covering 17,500 shares of common stock at an exercise price of $16 per share on February 5, 2026.
According to the vesting terms, 25% of the option vests on the one-year anniversary of the February 5, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service. After this grant, Viret directly holds derivative securities representing 17,500 underlying shares.
SpyGlass Pharma, Inc. Chief Executive Officer and director Patrick H. Mooney reported the acquisition of a stock option grant for 300,000 shares of common stock. The option has an exercise price of $16 per share and is held as a direct ownership position.
The grant vests over four years starting from a vesting commencement date of February 5, 2026. Twenty-five percent of the shares vest on the one-year anniversary of that date, and the remaining shares vest in equal monthly installments thereafter, contingent on Mr. Mooney continuing as a service provider.